Zacks Investment Research Upgrades OraSure Technologies (OSUR) to “Hold”

Zacks Investment Research upgraded shares of OraSure Technologies (NASDAQ:OSUR) from a sell rating to a hold rating in a report issued on Saturday, December 30th.

According to Zacks, “OraSure Technologies, Inc. develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. OraSure Technologies is the leading supplier of oral-fluid collection devices and in vitro diagnostic assays to the employment, criminal justice, drug treatment, life insurance and public health markets for the detection of abused drugs and the antibodies to HIV. Based in Bethlehem, Pennsylvania, the Company develops, manufactures and markets oral specimen collection devices, in vitro diagnostic tests, and other medical devices. “

Other analysts also recently issued research reports about the stock. Jefferies Group reissued a buy rating and issued a $23.00 price objective on shares of OraSure Technologies in a report on Friday, October 20th. Canaccord Genuity reaffirmed a buy rating and set a $22.00 price target on shares of OraSure Technologies in a report on Tuesday, September 19th. BidaskClub raised shares of OraSure Technologies from a hold rating to a buy rating in a report on Thursday, December 21st. Finally, ValuEngine downgraded shares of OraSure Technologies from a buy rating to a hold rating in a report on Thursday, November 2nd. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. OraSure Technologies currently has an average rating of Buy and a consensus target price of $19.65.

OraSure Technologies (NASDAQ OSUR) opened at $19.81 on Friday. OraSure Technologies has a 52 week low of $8.39 and a 52 week high of $23.01. The company has a market cap of $1,197.80, a PE ratio of 37.98, a P/E/G ratio of 4.43 and a beta of 1.27.

OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.09 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.09. The business had revenue of $42.30 million for the quarter, compared to analyst estimates of $40.87 million. OraSure Technologies had a net margin of 20.48% and a return on equity of 14.12%. OraSure Technologies’s quarterly revenue was up 31.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.11 EPS. equities research analysts expect that OraSure Technologies will post 0.43 earnings per share for the current year.

In related news, Director Mara G. Aspinall acquired 5,000 shares of the stock in a transaction that occurred on Tuesday, November 7th. The stock was acquired at an average cost of $14.23 per share, for a total transaction of $71,150.00. Following the transaction, the director now directly owns 5,000 shares in the company, valued at $71,150. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 6.40% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Pinebridge Investments L.P. acquired a new position in OraSure Technologies in the 2nd quarter valued at approximately $131,000. Oppenheimer Asset Management Inc. acquired a new position in OraSure Technologies in the 3rd quarter valued at approximately $186,000. Victory Capital Management Inc. increased its position in OraSure Technologies by 17.6% in the 2nd quarter. Victory Capital Management Inc. now owns 9,070 shares of the medical instruments supplier’s stock valued at $157,000 after acquiring an additional 1,360 shares during the period. ARP Americas LLC acquired a new position in OraSure Technologies in the 3rd quarter valued at approximately $221,000. Finally, Noesis Capital Mangement Corp acquired a new position in OraSure Technologies in the 3rd quarter valued at approximately $225,000. Hedge funds and other institutional investors own 94.43% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Zacks Investment Research Upgrades OraSure Technologies (OSUR) to “Hold”” was originally posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this story on another website, it was stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this story can be read at https://www.thelincolnianonline.com/2018/01/14/orasure-technologies-osur-rating-increased-to-hold-at-zacks-investment-research-updated-updated.html.

OraSure Technologies Company Profile

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Get a free copy of the Zacks research report on OraSure Technologies (OSUR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply